Search
PTC Therapeutics Inc
PTCTAdd to Watchlist
78.980USD
+0.450+0.57%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
6.55BMarket Cap
8.27P/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-18The current earnings forecast score of PTC Therapeutics Inc is 8.00, ranking 55 out of 157 in the Pharmaceuticals industry. The average price target is 80.00, with a high of 118.00 and a low of 55.00.
Analyst Rating
Based on
15
analysts
Buy
Current Rating
93.286
Target Price
+18.11%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
175
Total
6
Median
8
Average
Company name
Ratings
Analysts
PTC Therapeutics Inc
PTCT
15
Biogen Inc
BIIB
38
Amgen Inc
AMGN
38
Eli Lilly and Co
LLY
35
AbbVie Inc
ABBV
34
Vertex Pharmaceuticals Inc
VRTX
34
1
2
3
...
35
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is PTC Therapeutics Inc's expected revenue for the next quarter?
PTC Therapeutics Inc's expected revenue is 293.06M.
What is PTC Therapeutics Inc's price target?
Analysts forecast that PTC Therapeutics Inc's price target is USD 80.00, with the highest forecast at USD 118.00 and the lowest forecast at USD 55.00.
How have PTC Therapeutics IncPTCT's recent earnings per share performed?
The market expectation was USD -0.03, while PTC Therapeutics IncPTCT's earnings per share (EPS) for the previous quarter was USD -1.64. EPS for the next quarter is expected at USD 0.26.
What is the analyst rating for PTC Therapeutics Inc?
Based on the ratings of PTC Therapeutics Inc's stock from 15 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
